Tau immunotherapies have advanced from proof-of-concept studies to over a dozen clinical
trials for Alzheimer's disease (AD) and other tauopathies. Mechanistic studies in animal and …

Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to
improve the accuracy by which specific causes of dementia can be diagnosed in vivo …

The majority of clinical trials targeting the tau protein in Alzheimer's disease and other
tauopathies are tau immunotherapies. Because tau pathology correlates better with the …

Tau immunotherapies have now advanced from proof-of-concept studies to Phase II clinical
trials. This review briefly outlines developments in the field and discusses how these …

Frontotemporal dementia (FTD) is one of the most common neurodegenerative diseases,
encompassing a myriad of different, clinically distinct subtypes which all target the …

Background: Differential diagnosis in dementia is at present one of the main challenges both
in clinical practice and research. Cerebrospinal fluid (CSF) biomarkers are included in the …

Frontotemporal dementia (FTD) is the second commonest cause of young onset dementia.
Our understanding of FTD and its related syndromes has advanced significantly in recent …

Antibodies or their derivatives as imaging probes for pathological tau protein have great
potential, but have not been well studied. In particular, smaller, single-chain-variable …

Various proteins play a decisive role in the pathology of different neurodegenerative
diseases. Nonetheless, most of these proteins can only be detected during a …

As dementia is a fast-growing health care problem, it is becoming an increasingly urgent
need to provide an early diagnosis in order to offer patients the best medical treatment and …